Scientific publications.
At Myogem Health Company we are constantly evolving. Discover the latest updates on our research, advances in treatments, and relevant news in the field of Steinert's Myotonic Dystrophy.
Scientific article with a complete overview through 2022 of the most recent drug development programs undergoing preclinical and clinical evaluation.
View report
See moreDoctoral thesis
Highest qualification awarded by the Thesis Committee: Dr. Rafael Mañez Mendiluce**, Dr. Carmen Escolano Mirón***, Arturo López Castel****
See moreScientific article compiling the most recent drug development projects currently in the preclinical and clinical phases
View report
See moreMyogem’s MyoDM clinical study successfully completes patient recruitment. Post on LinkedIn
At the end of February 2021, the patient recruitment phase of the clinical study NCT04634682 by Myogem concluded. The study...
See moreMyogem Initiates Clinical Study of MyoDM in Myotonic Dystrophy Type 1 (DM1)
DM1 is a rare or orphan neuromuscular disease that affects more than one million people worldwide. As a result of...
See moreRecognition with Seals of Excellence and Granting of the European R&D Project of the SME-1 program, to carry out the MyoDM clinical trials
Myogem Health Company S.L. and its project “New food for special medical purposes for the nutritional treatment of myotonic dystrophy...
See morePresentation of MyoDM Preclinical Results at the International Congress on Myotonic Dystrophy IDMC-12
Myogem presents the results of preclinical studies of the MyoDM food supplement in preclinical models of T1DM at the International...
See moreMyogem participates in the “Summer School” Spanish Edition of the European program “Eurordis”
Myogem participates in the Summer School Spanish Edition by Eurordis, a training program for patient representatives and researchers on information,...
See morePatent granted in USA 2019 and licensed to Myogem “COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY”
Note on Justia Patents: https://patents.justia.com/patent/10226467PATENT:Artero Allepuz, R. D., Castells Boliart, J., Borrell Bilbao, J. I., Llamusí Troísi, B., Bargiela Schönbrunn,...
See moreMyogem receives the Seal of Excellence
Myogem receives the Seal of Excellence from the European Commission under the H2020 SME Instrument Phase 1 research program for...
See morePatent granted in USA 2017 and licensed to Myogem “CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2”
Note on “Justia Patents”: https://patents.justia.com/patent/20170304309PATENT:Artero Allepuz, R., Castells Boliart, J., Borrell Bilbao, J. I., Llamusí Troísi, B., Bargiela Schönbrunn, A.,...
See moreDiscovery of Natural Xanthines as active molecules in models of Myotonic Dystrophy, presented at the International Congress on Myotonic Dystrophy IDMC-11
Discovery of Natural Xanthines as active molecules in Myotonic Dystrophy models. This is the result of the collaborative project presented...
See more
MyoDM, a breakthrough in the treatment of Steinert's Myotonic Dystrophy. Research and innovation at the service of your well-being.
Buy now¿Do you have any questions
or need more information?
Fill out the form and our team will respond as soon as possible.